Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The board today is like kimberlite. Many diamonds. Posts as this one and others from Bio, Senti and others are valuable gems of great value. Thank you all. The BATON system looks like a great technology to expand. Maybe NWBO is too valuable for a buyout and future of cancer treatments look bright. Patience is the order of the months ahead. Thank you all for sharing your knowledge and insights. There has never been anything like this band of posters here.
I am firm belief that NWBO might be the best risk/reward ever in Biotech. I imagine that after TLD NWBO will be inundated with requests from the top researchers throughout the world to collaborated to push all the paradigm shifting technologies of NWBO rapidly forward.
Excellent post Gary. Thank you Sir.
If that is not enough for one to look at NWBO as a very long term investment then one is not interested in long term investments.
The BATON system implications of future value and innovations of NWBO are starting to sink in.
Ok haha! You're buying!
If Motley Fool says stay away from a stock I take a close look to see if I should take a long position. I have been following MF since MF began in early days of internet and they are almost the worse ever. MF claims Amazon as a pick that proves they are good at stock picking. But Motley Fool warned investors to stay away from Amazon for years they only in last few years revised history to claim they recommended Amazon.
CAR-T is extremely expensive to produce. Presumably a CAR-T produced in the BATON system would be so much more efficient that the combined product of the BATON would be less expensive than the CAR-T produced in the current way.
So the date of the ASM should be announced on or before Cinco De Mayo.
I agree except that the Ken Griffins ( Citadel/CDEL) of the world own a lot of stock of Big Pharma as well as most every other established revenue producing company. But not to worry once NWBO breaks into the ranks of revenue producing rapidly growing Pharma these same entities and others such as Blackrock and Vanguard will own large chunks of NWBO after up list to a major market. Likely pushing the market cap of NWBO higher than anyone can imagine now.
The stock price being held low for now conditions retail who hold NWBO now to sell on 5x 10x or 25x of current price when try a market value might be 50x to 100x.
Few few opportunities as great as NWBO will ever be encountered by investors in their lifetimes. The risk/reward equation is off the charts spectacular.
That is a very astute observation. One would think if the Journal Article was in the final stages when the Annals article came out that it would be absolutely necessary to revise the NWBO DCVax-L Article to incorporate that important FDA External Controls Article.
This is not a dumb question and I think it is directly on target. The nature of the trial and the nature of the illness being treated almost assuredly means the results will be somewhere in the middle. This is why it is critical that TLD is released in conjunction with a Peer Reviewed Medical Journal.
Being a finance guy instead of a field expert might be a great advantage. NWBO is a company trying to bring a better treatment for a difficult cancer. Not a get rich quick scheme. So the question for investors should be not how high will NWBO fly when TLD is announced (because the stock could drop precipitously even with good TLD and glowing Journal) but whether NWBO can gain RA approval and be profitable in the long run. Hoping for a quick get rich from a Buy Out or large stock price increase on TLD is not investing It is gambling.
Finance guys I know and successful investors do not gamble.
In Biotech sometimes the best time to buy a particular company is after a trial failure if there is a path forward and there is cash on books so that a near term stock sale/equity raise is unlikely. Hot momo money will sell on binary events good or bad so they can move on to their next gamble.
Yes I get it. It is a volatile stock so people want to watch everyday. People would like the company to hold their hand through difficult times. But here is the deal: Companies that hold investors hands more often than not lead the shareholders down the "Primrose Path".
One might try as difficult as that might be to not watch everyday unless buying or selling. Check in less often and ONLY RELY ON SEC FILINGS.
Unless one is a trader the money to be made in stocks is by careful DD and accumulation and holding for MANY YEARS.
If one is a trader then one should not really care about updates or even the name of the company. Just the TICKER AND THE TAPE.
NWBO might be a penny stock but management does not act like it by issuing countless penny stock pump PRs.
Penny stock investors are used to those pump PRs and when they do not get them they falsely imagine that the company is "going off the rails"
Companies do not owe stockholders play by play updates. They are required to update shareholders quarterly in SEC filings except in narrowly defined exceptional circumstances.
One follows companies like IBM, Merck, GE and Boeing by reading the SEC filings. NWBO will update us in SEC filings. In fact one would, in penny stocks, be well served by ignoring all PRs and just read the SEC filings. SEC filings are the only communication from companies one can legally rely on.
Thank you for being the point of the spear of truth. NWBO legally owes nothing to shareholders outside of 10ks and 10qs in regards to positive news. Regulation FD does require "Materially Adverse Events" be reported in 4 days by way of 8k SEC filing. Positive news does not have that Reg FD requirement. I will defer to you for further nuances of Reg FD as you have schooled me on this grey area in the past and I trust your reading on the subject. However I firmly believe had the trial failed on some bright line determination that the trial failed SEC Regulations would MANDATE disclosure. Instead NWBO advances on all fronts: manufacturing, patents and quiet preparations.
NWBO should be valued 10x where is is now just on where is sits pre TLD. Mispriced.
One thing that I find remarkable these types of stocks sometimes skyrocket in price before the event everyone is waiting for. What will be the trigger? Other things can trip the trigger on computer algos.TLD for sure. Approval might be anticlimactic or maybe not. My strategy is find good companies and hold forever. Never try to time the market other than to buy near the bottom of a well defined regression channel on the recovery or change in trend.
T
NWBO is the real deal IMHO and will sell blue chips to
Inrease holdings.
Of course. Overall Survival is the point of cancer treatments. Everything else including progression free survival is a short cut and not appropriate for a trial with a long fat tale of survivors. NWBO DcVax-L data should be extraordinary.
New SOC that is why there is so much FUD in opposition. Who's OX is eviscerated?
Good news is we can buy more stock at 10% of real intrinsic value. Right now!
At $3.50 - $5.00 it is a good buy that is where Institution will buy in putting a floor on the stock and where many retail will sell. Let you winners run! But at $0.75 it is an incredible buy.
NWBO is the 25x opportunity of 2022-2024.
Néed I remind everyone of Arrowhead and Anavex which 25x increased in 18 month's?
Relax the Linda's got this.
Not investment advice. But personally I think it is the best risk/reward in the market in years.
It will not take a lot of stock to make one comfortable. A large holding might make one a philanthropist. These are the aspirations of many NWBO investors.
Linda Powers got this. Stand by for windfall and let the company do the heavy lifting.
Up to you.
Northwest Bio. Shock & Awe.
50x in 24-36 months. No need for buy out but patience is critical.
What will be a kick in the teeth for Green Bay is if it turns out that Rogers without Adams is not nearly as good and production goes way down. Watch Derrick Carr's production go way up once he and Adams get synced up knowing what to expect from him.
I read it. It is a long term safety trial extension of the HIV monotherapy trial, not the combo therapy of which CYDY is working on submitting the BLA. So this is to advance the next indication after the combo trial in HIV in multidrug resistant patients.
This is a great post as is the very important post linked there in. I suggest everyone read it.
Imagine a bus ride up the Andes Mountains. Let the bus driver take his time as is a narrow road with no guard rails and steep cliffs on one side of the road.
This article reminds everyone that external controls are valid before the release of NWBO TLD DCVax-L. Specifically mentioning Neuro-Oncology as an example of the most appropriate fields to use external controls.
There NWBO goes again multitasking and getting all important IP foundational work done before TLD and partnership or buyout. They need the patents to get the best price for licensing or buyout. The intrinsic value of NWBO just took a giant leap higher.
Gary there is no time requirement to trade above a certain level of stock price. I have had stocks I own reverse split and up list the very next day totally by surprise to the market. There is the requirements of $20 million in shareholders equity so NWBO would need to sell shares or get an infusion of cash that is not classified as debt on the balance sheet.
CT156/24- Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after the introduction of the anti-CCR5 drug Leronlimab April 11, 2022 1.30-5.00 pm AACR annual meeting New Orleans, LA
CytoDyn presenting results of TNBreastCancer trial results at at annual meeting of AACR April 11th 1.30- 5.00 pm. This could change the trajectory of CYDY stock and could result in partnership offers for TNBCancer with Leronlimab.
The NWBO trial is unprecedented on many levels. What we are expecting is a major paradigm shift. Not merely like an earthquake and Tsunami but like a major tectonic shift of the type that are the genesis of mountain ranges. We are in the age before this major shift. After the NWBO technology is accepted the entire landscape of cancer treatment may change.
Many have posited possible reasons for delay. The one I favor is that this trial and results is a HUGE Deal. One shot so take time and get it right.
I appreciate your thoughts and contributions. However on this particular point I believe data lock means exactly that so after data lock there might not be any opportunities to go back to the clinical sites to collect more data.
Frank Zappa's penguins. Boing!
Pradon me if this is a crude analogy. So as you describe Car-T is a kin to a Seal Team sent to attack and kill a specific target of the worst offending Cancer Cells and then leave. While DcVax-L may be more like a team of instructors sent in to train the native immune system cells specific to the individual immune system to attack the cancer cells and continue fighting throughout the body until the war is won or lost? Does this explain the lower rate of metastases for the patients treated with DcVax--L?
Biosectinvestor I must commend you for your diligence and vigor in "correcting" many misguided, confused or mal-intentioned ideas and contentions.
Bravo!
We see a similar thing in Ukraine where the Russians are now flying the false flag of the old Soviet Union (unbelievable but true)on the armoured vehicles and tanks in their "Police Action" against Ukraine.
WTH is going on with this stock when many oppose vehemently and incessantly when neither own nor short the stock (no one is stupid enough to short a penny stock where they need $2.50 share cash held captive in margin for each share) only shorts are those exempt from FINRA margin because account held short is greater than $25 million. They hold them all short so not many blow up at once so usually ok.
Funny not funny but the long holders of NWBO just might be on the right side of history.
The "Market" is supposedly forward looking but also wears blinders. In 1999 Gilead was doubted as "everyone knew" can not treat viruses with drugs. GILD traded $8-10 ($1.60-$2) split adjusted.
Arrowhead languished for years sub $2 and shot up to $70 plus in 18 months in 2018 even before any approvals as the "Market" finally 'Got It" that they had a new technology of gene silencing that the "Market" previously did not understand.
The big gains in NWBO will be when the Market Gets It. That will likely be on TLD and Journal. Actual approval of DcVax-L might be anticlimactic, however further trials should add further catalysts for the stock price.
In any development pre revenue investment there are dangers in being too early and being too late. Too early is over and might be the reason some former investors remain so bitter. It is not too late and as you say the inflection point can come as early as next week. Immediate 5x to 10x is not out of the question and a 25x in just a few weeks is possible as what happened to Avavex Life Sciences just about a year ago following the same trajectory of a few years earlier in Arrowhead.
Next week or a few weeks. NWBO is pregnant we just can not tell exactly when she will give birth to DCVax-L because we do not know the gestation period. Only a fool would think it will be a still birth due to the careful prenatal care this has received and the accelerating preparations that have been made by those that are privy to the sonograms.
BTW the Lindas' baby is a Girl as she is likely to give birth many more beautiful and elegant offspring for other cancers.
Being as involved as you are in Medicine and clinical trials I trust your instincts of what is likely going on behind the scenes.
Also what we have seen in the progress that has been released to the public or has been revealed in public filings such as patent filings and manufacturing advances that the process is moving forward and accelerating so one would surmise the "under surface" movements have been accelerating as well.
Comparing the submissions of research papers in botany or agriculture to "Nature" to submissions of results of clinical trials to Medical Journals would intuitively be completely different, as you have explained. Especially in this instance.
Telling like it is. Great response to an attempt to sew doubt by diverting attention to some other early stage trials.
There seems to be a lot of debate over things that have strong empirical evidence. Many still doubt the NWBO cancer vaccine can prove efficacy where the blinded results make it extremely unlikely that it is not useful for brain cancer where the measure of success is longer life of a better quality.
Of the subject you replied to: That is right the polar ice caps are shrinking and sea level is concommitaly rising and oceans are getting warmer. This is all empirical evidence of climate change. What is debated in science/economics is how to best deal with it. What are the man made contributing factors is debated as well as the best ways to modify those behaviors are also debated. Lowering carbon foot prints would have other benefits as well. Ice Ages ebb and flow the Ice Caps have been shrinking since the last Ice Age. Thousands of years. So it is not That the Ice Caps are shrinking that is the concern but rather the acceleration of the rate. Eventually there will be increased volcanic activity that will cool the Earth and start heading to the next Ice Age. So the questions are how to best minimize the human footprint on Earth to enjoy the favorable benefits of a healthy environment. The health of the planet depends on the health of the Oceans. That is why Environmental Scientists focus on the Worlds Great Coral Reefs. They are dying at an alarming rate. If one dives some of these reefs often one will meet those scientists diving them as well.
Some of the most vibrant reefs of just a few decades ago are now bare bleached white dead coral. Man did this. More likely from ocean pollution rather than Air Pollution but both contribute.
There is a lot of honest scientific debate in this arena and it will not end soon.
What will end soon is the scientific debate regarding the efficacy of NWBO's brain cancer vaccine. As a scientist I see the trend of evidence that strongly suggests the efficacy of NWBO cancer vaccine.
The statutes of limitarmtion is likely up for this Phase 5 Short seller. However the Feds can use it to "Bitch" the defendants with RICO crimes if they bring charges on later crimes resulting in long 10-20 year mandatory prison with no parole by showing pattern and practice of this type of racketeering.
Volcanos signal when they are about to erupt. Rumbling and swelling of the flanks of the caldera.
Short attack on NWBO today and insider selling of possibly a casualty of NWBO ..Novacure.
He we come ....Anak Krakatoa!
Thanks for your input today. Have a great evening. I am trusting management and just along for the ride.
Some of the same brokers s throttled back buying making it difficult for some retail to buy today. Like what Robinhood and others did with GME/AMC when shorts were trying to cover. I smell short covering and that the drop to lows near end of day could have been "positioning" to allow short covering. Shortsellers might see new short targets that look good now or getting an uneasy feeling that Good TLD will come out soon.
Get this it could trade multibillions of shares. Houston American Energy HUSA traded 199 millions shares today. Twenty times the entire shares issued of 9.9 million shares. It closed up 500% and still after hours holding up. Sometimes this happens. If fact just about everytime it happens that stocks in a violent parabolic move up trade many times the issued shares. But almost never does this on a down spike day. HFT and naked shorts are some of the speculated reasons.
The Market is forward looking the Scientists and Consultants for the Whales will look at the TLD and discount appropriately then bid NWBO stock up based on likelihood of approval. The cancer victims will benefit most from approval. The shareholders will make their largest gains based on strength of TLD.
This is straight out of Phase 5 (the short seller) discredited short and distort report from 2016. Just substitute Advent for Cognate.
SMH
Short sleeper cell plant?